The Department for Health and Social Care has asked NICE to conduct an appraisal of idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies.
Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed.
As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes.